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1. Introduction 
Dihydrofolate reductase (DHFR, EC 1.5.1.3) catal- 
yses the NADPH-dependent reduction of dihydrofolate 
to tetrahydrofolate; further metabolites of tetrahy- 
drofolate are involved in the incorporation of single- 
carbon units into purines, pyrimidines and amino 
acids [ 1,2]. The inhibition of DHFR can therefore 
lead to a deficiency of the components of nucleic 
acids and proteins, to eventual cessation of DNA syn- 
thesis and hence to cell death. DHFR inhibitors are 
used in the control of a number of disease processes 
including various tumours and bacterial infections. 
Understanding of inhibitor binding at the molecular 
level is of potential value in the design of drugs having 
greater inhibitory potential and improved selectivity 
towards the appropriate organism. Trimethoprim 
(TMP), a widely used antibacterial drug [3-61, is a 
potent inhibitor of bacterial DHFRs but a much 
weaker inhibitor of the vertebrate enzymes (e.g., ICse 
values against Escherichia coli and human enzyme 
[7] are, respectively, 5 X lo-’ M and 3 X lo4 M). 
To provide information on the action of this drug at 
the molecular level, we have determined the structure 
of the binary complex of E. coli (strain RTSOO) form 
I DHFR with TMP and compared it with that of the 
complex of DHFR with methotrexate (MTX), a drug 
which binds tightly to both bacterial and vertebrate 
DHFR. The structure of our TMP-enzyme complex 
differs from that in [8] of an MTX-enzyme complex 
from a different strain (MB1428) ofE. coli. The amino 
acid sequences of the two enzymes are currently 
thought to differ at 3 positions [9]. 
2. Experimental 
Escherichia coli (RT500) form I DHFR was pre- 
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pared as in [lo] and was crystallized from aqueous 
ethanol by vapour diffusion. Hexagonal bipyramidal 
crystals, space group P6r, with axial length of up to 
1.2 mm grew in -1 month. The unit cell dimensions 
(a = b = 93.6 A; c = 73.9 A) were similar whether 
crystals were grown in the presence of TMP or MTX 
and resemble those reported for the MTX-enzyme 
complex in [8]. One isomorphous heavy atom deriv- 
ative was prepared by soaking DHFR-TMP crystals 
in saturated solutions of sodium diuranate, another 
by growing crystals in the presence of dithiothreitol 
and transferring them to a solution containing ethyl- 
mercuriphosphate. X-ray data were collected using an 
automatic [ 1 l] rotation camera (Enraf Nonius) and a 
graphite monochromator (StBe). Heavy atom sites 
were located by difference Patterson and difference 
Fourier functions. The parameters for 1 uranium and 
7 mercury sites were refined by minimisation of lack 
of closure [ 121 and data to a minimum spacing of 
2.8 A were used in the calculation of electron density 
maps. Two protein molecules in the crystallographic 
asymmetric unit were located in maps plotted at a 
scale of 0.15 cm/A and, with the aid of the amino 
acid sequence of the enzyme [13], the peptide chain 
was traced in maps at a scale of 0.75 cm/A. Kendrew 
skelelal models were fitted to maps at a scale of 
2.0 cm/A using a modified design of the optical com- 
parator devised in [ 141. 
3. Results and discussion 
The overall folding of the polypeptide backbone is 
substantially in accord with that in [8] for the E. coli 
DHFR-MTX complex. An 8-stranded P-sheet begins 
at the N-terminus and ends, with its only antiparallel 
strand, at the C-terminus. Viewed in the direction of 
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Fig.1. Schematic illustration of the binding site for TMP in E. coli DHFR. Nitrogen atoms are shown black, oxygen striped. Only 
those side chains which might interact with TMP are shown. Three segments of peptide chain form the rear of the binding cleft 
and these are adjacent strands in the P-sheet (E, A and F in the nomenclature of [8]). The left-hand side of the cleft is formed by 
irregular peptide chain whilst the right-hand side contains an irregular region and contiguous helix (B). The diaminopyrimidine 
ring is shown surrounded by Asp 27, Phe 31, Be 94, Thr 113, and the protein chain between Be 5 and Ala 7. Tyr 100 is omitted 
for clarity but would appear below and well behind the ring. The trimethoxybenzyl moiety of TMP is partially enclosed by the 
Phe 31 above, Be 50 on the left and Leu 28 on the right, the latter two groups being situated at the entrance to the cleft. 
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the strands, the sheet shows the usual right-handed 
twist [15]. 
The binding of TMP is similar in each of the two 
molecules in the asymmetric unit; it lies in a promi- 
nent cleft having irregular and helical peptide chain 
on one side and irregular chain on the other (fig.1). 
The face of the P-sheet closes the cleft at the rear. Nl 
and the 2-amino group of TMP are -3 A from the 
carboxyl oxygens of Asp 27. The side chain of Phe 31 
is close to the pyrimidine and benzyl methylene of 
TMP while Ile 94 is also close to this methylene and 
to the 4-amino group. Thr 113 is near the 2-amino 
group and may accept a hydrogen bond from it. The 
4-amino group, C2 and N3 are all close to the first 
P-strand, in the region of residues 5-7. The 4-amino 
group is in the vicinity of the hydroxyl substituent of 
Tyr 100 but it is not clear whether the oxygen and 
nitrogen atoms are close enough to form a hydrogen 
bond. The phenyl ring of TMP is directed outwards 
from the enzyme cleft with the ring plane roughly 
aligned with the cleft. The sidechain of Ile 50 is close 
to the 4’-methoxy group. The 3’-methoxy group ap- 
proaches Leu 28 on the other side and also the edge 
of the ring of Phe 3 1. 
Both TMP and MTX contain the diaminopyrimidine 
moiety. To establish whether there are similarities in 
the binding of this part of the 2 drugs we have also 
grown and observed DHFR-MTX crystals and have 
calculated the difference Fourier electron density 
between the MTX and TMP complexes. The difference 
features near the diaminopyrimidine rings are not iden- 
tical for the 2 molecules in the asymmetric unit. In 
molecule 1 only there are indications that the pyrim- 
idine ring of MTX may be slightly tilted relative to 
that in TMP away from the Phe 3 1. The carboxyl 
group of Asp 27 may also be slightly displaced away 
from Phe 3 1. There are also suggestions of small shifts 
in Phe 3 1 and Ile 50. No such differences have been 
detected in molecule 2. 
Without further refinement of the crystal structure 
it would be premature to offer explanations for such 
small differences. The essential similarity in the TMP 
binding to the 2 protein molecules suggests that the 
binding we observe is not substantially affected by 
crystal packing forces, despite the fact that the clefts 
of the 2 protein molecules are in different environ- 
ments within the crystal and are therefore subject to 
non-equivalent perturbations. In [8] there was a dif- 
ference in hydrogen bonding between the protein and 
the glutamate moiety of MTX in the 2 molecules of 
their complex, and comparable small differences may 
become apparent when the current TMP complexes 
are refined. 
The dissociation constant for TMP in the binary 
complex withE. coli enzyme has been estimated [ 161 
as 15 nM and the observed structure of the complex 
between DHFR and TMP provides some insight into 
the source of the binding energy for this drug. The 
diaminopyrimidine ring interacts with the protein 
both ionically and through hydrogen bonding and 
there are many Van der Waal’s contacts between pro- 
tein and drug. The observed conformation of TMP in 
the crystalline binary complex is compatible with that 
deduced by solution NMR studies [ 171 and similar to 
that observed in the crystal structure of TMP-HBr 
itself [ 18,191. The binding of the diaminopyrimidine 
moiety to an acidic group in the protein is consistent 
with an analysis [20] of UV difference spectra which 
indicated an increase in pK, of TMP upon binding to 
DHFR. 
The TMP geometry which we have observed in the 
DHFR-TMP binary complex is similar to that used 
to explain inhibition of the enzyme in the ternary 
complex by analogues of TMP [19,21]. Some struc- 
tural differences may exist between the binary and 
ternary complexes which could explain the observa- 
tion [lo] that the dissociation constant of TMP from 
the ternary complex is 0.1 nM and therefore -150.fold 
smaller than that for the binary complex. The possi- 
bility that these differences are small and localised is 
suggested by the observation that the protein back- 
bone and the inhibitor conformation in the ternary 
Z,. casei DHFR-MTX-NADPH complex is similar to 
that in the binary E. coli DHFR-MTX complex [22] 
despite the substantially different amino acid se- 
quences and the presence of cofactor in one of the 
complexes. To ascertain the extent of any such dif- 
ferences, we have grown and are studying crystals of 
the E. coli DHFR-TMP-NADPH complex. (These 
differ in form from the crystals of the E. coli DHFR- 
TMP complex.) 
We also wish to understand why MTX, unlike TMP, 
inhibits mammalian DHFR much more effectively 
than bacterial DHFR. The structural features of MTX 
which give rise to this difference in binding energy 
would probably include: the pteridine group (in con- 
trast to the pyrimidine of TMP), a glutamate moiety, 
and a differently located benzene ring (due to its link- 
age with pteridine). It would be premature to hypoth- 
esize on these points at present, so to study this further 
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we have crystallised the mammalian enzyme and are 
now determining that structure. 
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